Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 4/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | OTUD7B | Q6GQQ9 | 2/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25421541 | 0.91 | XDH (0.41) | XDHPDE10AS1PR1S1PR5CSNK2A2 | |
| SCHEMBL25418143 | 0.88 | XDH (0.42) | XDHPDE10AS1PR1S1PR5CSNK2A2 | |
| SCHEMBL25613352 | 0.84 | FGFR4 (0.41) | XDHPDE10AS1PR1S1PR5CSNK2A2 | |
| SCHEMBL25613436 | 0.83 | PDE10A (0.42) | XDHPDE10AS1PR1S1PR5CSNK2A2 | |
| SCHEMBL25612826 | 0.82 | XDH (0.43) | XDHS1PR1S1PR5P2RX3CSNK2A2 | |
| SCHEMBL25605336 | 0.77 | MKNK1 (0.59) | XDHS1PR1S1PR5 | |
| SCHEMBL25613441 | 0.77 | USP30 (0.41) | XDHS1PR1S1PR5 | |
| SCHEMBL25420455 | 0.75 | CSNK2A2 (0.41) | PDE10ACSNK2A2CSNK2A1KDR | |
| SCHEMBL30481263 | 0.75 | CSNK2A2 (0.41) | PDE10ACSNK2A2CSNK2A1KDR | |
| SCHEMBL25421729 | 0.74 | USP30 (0.41) | XDHS1PR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727939-A1 | 5-(CINNOLIN-6-YL)THIAZOLE COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2026-04-22 | — | — | EP | disclosed |
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | PROTHENA BIOSCIENCES INC | 2025-02-27 | — | — | US | disclosed |
| WO-2024259116-A1 | 5-(CINNOLIN-6-YL)THIAZOLE COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2024-12-19 | — | — | WO | disclosed |
| WO-2023107714-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | DYRK1A, DYRK2, DYRK1B | XDH 1447/4885PDE10A 1122/4885S1PR1 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.